Platelet Aggregation Inhibitors Clinical Trial
Official title:
MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)
Verified date | March 2019 |
Source | Ospedale Santa Croce-Carle Cuneo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation. It seeks to determine if initiation of a prolonged cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and whether a cangrelor infusion before cardiac and non cardiac procedures is safe.
Status | Not yet recruiting |
Enrollment | 140 |
Est. completion date | January 1, 2021 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Provide written informed consent before initiation of any study related procedures. 2. Be = 18 years of age. 3. Have received any dose of a P2Y12 inhibitor (clopidogrel, ticlopidine, prasugrel, or ticagrelor) at any dose within at least 48 hours prior to randomization. 4. Patients undergoing non deferrable cardiac or non cardiac surgery which requires discontinuation of P2Y12 inhibitor due to a significant bleeding risk. Exclusion Criteria: 1. Confirmed of suspected pregnancy (if woman of child-bearing potential) or lactating females 2. Active bleeding with evident contraindications to DAPT 3. Patients requiring oral anticoagulant therapy 4. PCI within 1 month 5. Intracranial neoplasm or history of intracranial surgery 6. History of bleeding diathesis 7. Thrombocytopenia (platelet count of less than 100,000/µL) 8. Known International Normalized Ratio (INR) greater than 1.5 at screening. 9. Requirement for dialysis treatment (hemodialysis or peritoneal) 10. Estimated Glomeular filtration rate eGFR <30 ml/min 11. Administration of abciximab within 24 hours of randomization or administration of eptifibitide or tirofiban within 12 hours of randomization 12. Plans to continue oral anticoagulant or P2Y12 inhibitors or cangrelor in the pre-operative period 13. Refusal to receive blood transfusion 14. Receipt of fibrinolytic therapy in the 12 hours preceding randomization 15. Allergy, hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose 16. High likelihood of being unavailable for follow-up 17. Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization 18. Any disease or condition which, in the judgment of the investigator, would place the patient at undue risk by being enrolled in the trial |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ospedale Santa Croce-Carle Cuneo |
Albaladejo P, Marret E, Samama CM, Collet JP, Abhay K, Loutrel O, Charbonneau H, Jaber S, Thoret S, Bosson JL, Piriou V. Non-cardiac surgery in patients with coronary stents: the RECO study. Heart. 2011 Oct;97(19):1566-72. doi: 10.1136/hrt.2011.224519. Epub 2011 Jul 26. — View Citation
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25. Review. Erratum in: Circulation. 2017 Mar 7;135(10 ):e646. Circulation. 2017 Sep 5;136(10 ):e196. — View Citation
Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007 Jun 5;49(22):2145-50. Epub 2007 May 23. Review. — View Citation
Moschovitis A, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2006. EuroIntervention. 2010 Jun;6(2):189-94. doi: 10.4244/. — View Citation
Rossini R, Musumeci G, Capodanno D, Lettieri C, Limbruno U, Tarantini G, Russo N, Calabria P, Romano M, Inashvili A, Sirbu V, Guagliumi G, Valsecchi O, Senni M, Gavazzi A, Angiolillo DJ. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost. 2015 Feb;113(2):272-82. doi: 10.1160/TH14-05-0436. Epub 2014 Oct 2. — View Citation
Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, Hoeks SE, Poldermans D. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007 Jan 2;49(1):122-4. Epub 2006 Dec 18. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | LEVEL OF RESIDUAL PLATELET REACTIVITY | Accriva VerifyNow P2Y12 assay | 1-2 hours | |
Secondary | ischemic and hemorrhagic endpoints | Bleeding Academic Research Consortium (BARC) grade > 3 | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
Recruiting |
NCT04796714 -
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
|
Phase 4 | |
Completed |
NCT02711410 -
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients
|
N/A | |
Completed |
NCT05278637 -
GM03 - Platelet RNA Signatures of Aspirin
|
Early Phase 1 | |
Recruiting |
NCT03288441 -
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
|
||
Recruiting |
NCT05306951 -
Correct Timing of Head Imaging in Trauma
|
||
Recruiting |
NCT05732701 -
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
|
N/A | |
Recruiting |
NCT05702463 -
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
|
Phase 1 | |
Completed |
NCT01354808 -
ACCEL-LOADING-ACS Study
|
Phase 4 | |
Completed |
NCT00799396 -
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
|
Phase 4 | |
Completed |
NCT00325390 -
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
|
Phase 3 | |
Completed |
NCT04999293 -
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
|
||
Completed |
NCT04328883 -
Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin
|
Phase 1 | |
Completed |
NCT02808767 -
Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction
|
Phase 4 | |
Completed |
NCT00769938 -
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
|
Phase 4 | |
Completed |
NCT03599284 -
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
|
Phase 2 | |
Completed |
NCT03785509 -
The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
|
||
Unknown status |
NCT01103843 -
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
|
N/A | |
Active, not recruiting |
NCT03462498 -
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
|
Phase 4 |